Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus

Abstract Use of galectin-3 for assessing cardiac function in prediabetes and type 2 diabetes mellitus (T2DM) needs to be established. Within the Gutenberg Health Study cohort (N = 15,010, 35–74 years) patient characteristics were investigated regarding galectin-3 levels. Prognostic value of galectin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Volker H. Schmitt, Jürgen H. Prochaska, Annegret S. Föll, Andreas Schulz, Karsten Keller, Omar Hahad, Thomas Koeck, Sven-Oliver Tröbs, Steffen Rapp, Manfred Beutel, Norbert Pfeiffer, Konstantin Strauch, Karl J. Lackner, Thomas Münzel, Philipp S. Wild
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1271f9e7354d4fb6bc7fa4de94870c45
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1271f9e7354d4fb6bc7fa4de94870c45
record_format	dspace
spelling	oai:doaj.org-article:1271f9e7354d4fb6bc7fa4de94870c452021-12-02T17:27:03ZGalectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus10.1038/s41598-021-98227-x2045-2322https://doaj.org/article/1271f9e7354d4fb6bc7fa4de94870c452021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98227-xhttps://doaj.org/toc/2045-2322Abstract Use of galectin-3 for assessing cardiac function in prediabetes and type 2 diabetes mellitus (T2DM) needs to be established. Within the Gutenberg Health Study cohort (N = 15,010, 35–74 years) patient characteristics were investigated regarding galectin-3 levels. Prognostic value of galectin-3 compared to NT-proBNP concerning cardiac function and mortality was assessed in individuals with euglycaemia, prediabetes and T2DM in 5 years follow-up. Higher galectin-3 levels related to older age, female sex and higher prevalence for prediabetes, T2DM, cardiovascular risk factors and comorbidities. Galectin-3 cross-sectionally was related to impaired systolic (β − 0.36, 95% CI − 0.63/− 0.09; P = 0.008) and diastolic function (β 0.014, 95% CI 0.001/0.03; P = 0.031) in T2DM and reduced systolic function in prediabetes (β − 0.34, 95% CI − 0.53/− 0.15; P = 0.00045). Galectin-3 prospectively related to systolic (β − 0.656, 95% CI − 1.07/− 0.24; P = 0.0021) and diastolic dysfunction (β 0.0179, 95% CI 0.0001/0.036; P = 0.049), cardiovascular (hazard ratio per standard deviation of galectin-3 (HRperSD) 1.60, 95% CI 1.39–1.85; P < 0.0001) and all-cause mortality (HRperSD 1.36, 95% CI 1.25–1.47; P < 0.0001) in T2DM. No relationship between galectin-3 and cardiac function was found in euglycaemia, whereas NT-proBNP consistently related to reduced cardiac function. Prospective value of NT-proBNP on cardiovascular and all-cause mortality was higher. NT-proBNP was superior to galectin-3 to assess reduced systolic and diastolic function.Volker H. SchmittJürgen H. ProchaskaAnnegret S. FöllAndreas SchulzKarsten KellerOmar HahadThomas KoeckSven-Oliver TröbsSteffen RappManfred BeutelNorbert PfeifferKonstantin StrauchKarl J. LacknerThomas MünzelPhilipp S. WildNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Volker H. Schmitt Jürgen H. Prochaska Annegret S. Föll Andreas Schulz Karsten Keller Omar Hahad Thomas Koeck Sven-Oliver Tröbs Steffen Rapp Manfred Beutel Norbert Pfeiffer Konstantin Strauch Karl J. Lackner Thomas Münzel Philipp S. Wild Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus
description	Abstract Use of galectin-3 for assessing cardiac function in prediabetes and type 2 diabetes mellitus (T2DM) needs to be established. Within the Gutenberg Health Study cohort (N = 15,010, 35–74 years) patient characteristics were investigated regarding galectin-3 levels. Prognostic value of galectin-3 compared to NT-proBNP concerning cardiac function and mortality was assessed in individuals with euglycaemia, prediabetes and T2DM in 5 years follow-up. Higher galectin-3 levels related to older age, female sex and higher prevalence for prediabetes, T2DM, cardiovascular risk factors and comorbidities. Galectin-3 cross-sectionally was related to impaired systolic (β − 0.36, 95% CI − 0.63/− 0.09; P = 0.008) and diastolic function (β 0.014, 95% CI 0.001/0.03; P = 0.031) in T2DM and reduced systolic function in prediabetes (β − 0.34, 95% CI − 0.53/− 0.15; P = 0.00045). Galectin-3 prospectively related to systolic (β − 0.656, 95% CI − 1.07/− 0.24; P = 0.0021) and diastolic dysfunction (β 0.0179, 95% CI 0.0001/0.036; P = 0.049), cardiovascular (hazard ratio per standard deviation of galectin-3 (HRperSD) 1.60, 95% CI 1.39–1.85; P < 0.0001) and all-cause mortality (HRperSD 1.36, 95% CI 1.25–1.47; P < 0.0001) in T2DM. No relationship between galectin-3 and cardiac function was found in euglycaemia, whereas NT-proBNP consistently related to reduced cardiac function. Prospective value of NT-proBNP on cardiovascular and all-cause mortality was higher. NT-proBNP was superior to galectin-3 to assess reduced systolic and diastolic function.
format	article
author	Volker H. Schmitt Jürgen H. Prochaska Annegret S. Föll Andreas Schulz Karsten Keller Omar Hahad Thomas Koeck Sven-Oliver Tröbs Steffen Rapp Manfred Beutel Norbert Pfeiffer Konstantin Strauch Karl J. Lackner Thomas Münzel Philipp S. Wild
author_facet	Volker H. Schmitt Jürgen H. Prochaska Annegret S. Föll Andreas Schulz Karsten Keller Omar Hahad Thomas Koeck Sven-Oliver Tröbs Steffen Rapp Manfred Beutel Norbert Pfeiffer Konstantin Strauch Karl J. Lackner Thomas Münzel Philipp S. Wild
author_sort	Volker H. Schmitt
title	Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus
title_short	Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus
title_full	Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus
title_fullStr	Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus
title_full_unstemmed	Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus
title_sort	galectin-3 for prediction of cardiac function compared to nt-probnp in individuals with prediabetes and type 2 diabetes mellitus
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/1271f9e7354d4fb6bc7fa4de94870c45
work_keys_str_mv	AT volkerhschmitt galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus AT jurgenhprochaska galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus AT annegretsfoll galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus AT andreasschulz galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus AT karstenkeller galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus AT omarhahad galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus AT thomaskoeck galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus AT svenolivertrobs galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus AT steffenrapp galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus AT manfredbeutel galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus AT norbertpfeiffer galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus AT konstantinstrauch galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus AT karljlackner galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus AT thomasmunzel galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus AT philippswild galectin3forpredictionofcardiacfunctioncomparedtontprobnpinindividualswithprediabetesandtype2diabetesmellitus
_version_	1718380774598639616

Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus

Ejemplares similares